drugset / Trial / NCT02741115

Fontan Udenafil Exercise Longitudinal Assessment Trial

NCT02741115

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the clinical efficacy and safety of udenafil, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of adolescent subjects who have undergone the Fontan procedure.

Timeline

Start
2016-07-22
Primary completion
2018-12-27
Completion
2019-04-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Udenafil Small molecule 87.5 mg Oral